Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097162 | 0.83 | CYP2D6 (0.33) | CYP2D6CYP1A2STS | |
| SCHEMBL10097193 | 0.81 | CYP2D6 (0.34) | CYP2D6CYP1A2STSALDH1A1TP53 | |
| SCHEMBL10097202 | 0.79 | CYP2D6 (0.34) | CYP2D6CYP1A2ALDH1A1TP53POLB | |
| SCHEMBL10097210 | 0.76 | LMNA (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10096990 | 0.75 | CYP2D6 (0.31) | CYP2D6CYP1A2 | |
| SCHEMBL10097184 | 0.74 | SMN1; SMN2 (0.38) | CYP2D6CYP1A2ALDH1A1TP53POLB | |
| SCHEMBL10096949 | 0.73 | MEN1 (0.30) | CYP2D6CYP1A2KMT2A | |
| SCHEMBL10097982 | 0.73 | KMT2A (0.37) | CYP2D6ALDH1A1TP53POLBKMT2A | |
| SCHEMBL10097203 | 0.69 | CYP1A2 (0.32) | CYP2D6CYP1A2KMT2A | |
| SCHEMBL10097208 | 0.69 | LMNA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124196-B2 | Fluorobicyclo[2.2.2]octane compound, method of producing the same, and applications thereof | FUJIFILM CORPORATION (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124196-B2 | Fluorobicyclo[2.2.2]octane compound, method of producing the same, and applications thereof | FUJIFILM CORPORATION (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20100231844-A1 | FLUOROBICYCLO[2.2.2]OCTANE COMPOUND, METHOD OF PRODUCING THE SAME, AND APPLICATIONS THEREOF | FUJIFILM CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100231844-A1 | FLUOROBICYCLO[2.2.2]OCTANE COMPOUND, METHOD OF PRODUCING THE SAME, AND APPLICATIONS THEREOF | FUJIFILM CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100231844-A1 | FLUOROBICYCLO[2.2.2]OCTANE COMPOUND, METHOD OF PRODUCING THE SAME, AND APPLICATIONS THEREOF | AFF2, FPR2, SLCO1A2 | CYP2D6 473/4885CYP1A2 130/4885STS 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.